BC Extra | Nov 22, 2017
Clinical News

Researchers use RWE to reproduce trial results

In an article published in the Journal of the American Medical Association, a team of Harvard researchers used real-world evidence from a U.S. health insurance database to replicate the results of a randomized clinical trial...
BioCentury | Aug 11, 2014
Strategy

Profusion of exclusions

Express Scripts Holding Co. 's 2015 formulary exclusions offer hope that companies can renegotiate once-excluded drugs back into coverage. But the pharmacy benefits manager appears to be expanding the number of drugs and drug classes...
BC Extra | Jul 14, 2014
Politics & Policy

India caps prices of 50 CV and diabetes drugs

India's National Pharmaceutical Pricing Authority ( NPPA ) Januvia sitagliptin from Merck & Co. Inc. (NYSE:MRK) and Volibo voglibose from Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA). The only non-insulin diabetes drugs included on India's list of essential...
BioCentury | Dec 16, 2013
Strategy

Out in the cold

New excluded drugs lists devised by pharmacy benefits managers are raising the hurdle for reimbursement of drugs the PBMs' pharmacy and therapeutics committees consider to be clinically equivalent to cheaper drugs. Drugs that are not...
BC Week In Review | Jun 10, 2013
Company News

Astellas, Boehringer Ingelheim sales and marketing update

Astellas and Boehringer's Nippon Boehringer Ingelheim Co. Ltd. launched Micamlo 80 mg telmisartan/5 mg amlodipine in Japan to treat hypertension. The product is already available in a 40 mg telmisartan/5 mg amlodipine dose. The combination...
BioCentury | May 13, 2013
Product Development

An association for dissociation

Forest Laboratories Inc. 's investment and option deal with Trevena Inc. last week will support the translation of a successful mechanism for treating chronic heart failure into the acute setting, as well as the development...
BC Week In Review | Oct 24, 2011
Clinical News

European Medicines Agency regulatory update

EMA's CHMP concluded that the benefit-risk balance of angiotensin receptor blockers (ARBs) is positive, and that evidence does not support an increased risk of cancer in patients on these drugs. CHMP conducted the review at...
BC Week In Review | Jun 6, 2011
Clinical News

Atacand candesartan cilexetil regulatory update

FDA completed a safety review of angiotensin receptor blockers (ARBs) and found no increased risk of cancer associated with the drugs. The agency said a meta-analysis of 31 trials with about 156,000 patients showed the...
BC Week In Review | Oct 18, 2010
Clinical News

Twynsta telmisartan/amlodipine regulatory update

The European Commission approved an MAA from Boehringer Ingelheim for Twynsta telmisartan/amlodipine to treat hypertension. The company plans to launch Twynsta in Europe as soon as possible. Twynsta is already approved in the U.S. Twynsta...
BC Extra | Oct 12, 2010
Company News

EC approves hypertension drug Twynsta

The European Commission approved an MAA from Boehringer Ingelheim GmbH (Ingelheim, Germany) for Twynsta telmisartan/amlodipine to treat hypertension. Twynsta is a combination of telmisartan, a small molecule angiotensin II receptor, and amlodipine, a calcium channel...
Items per page:
1 - 10 of 51